Nextera is attending the BIO International Convention in San Diego June 3 – 6, 2024! Please get in touch if you would like to meet us and learn more about our approach in engineered TCR-Like antibody guiding towards pHLA targets with transformational...
Harnessing the power of T cell immunity in the form of biologics holds tremendous potential in cancer immunotherapy. A new area of engineered guiding to pHLA with precision specificity and sensitivity beyond that of the natural T cell in the form of T cell engagers...
Nextera is attending the BIO Partnering @JPM Week 2024 in San Francisco, January 8 – 12, 2024. Please get in touch if you would like to meet us and learn more about our approach to next generation targeted immunotherapy!
CAR-based adoptive cell therapy (ACT) has shown a remarkable ability to treat and occasionally cure cancer by evoking or grafting an anti-cancer immune response into patients with hematological malignancies but has yet to show similar efficacy in solid tumors. In...
CEO/CSO Geir Åge Løset and Head of Business Development Francis Yuan will attend the BIO Europe 2023 in Munich, Germany, November 6 – 8. We are interested in discussing partnerships, collaborations, and asset out-licensing - please get in touch if you would like...
Factor-VII activating protease (FSAP) is a ubiquitously circulating zymogen plasma serine protease, which is rapidly activated upon tissue injury. FSAPs role in sepsis, trauma, stroke, and acute respiratory distress syndrome suggests that pro-FSAP activation is...
The antibody engineering field is steadily evolving harnessing improvements in discovery engines and computational methods. Together with collaborators at OUS/UiO (Norway) and John Hopkins (US), we here describe a very powerful combination of the highly efficient...
Nextera AS, a drug and target discovery company built on the unique and novel NextCore protein engineering and discovery platform, announces a strategic collaboration with Zelluna Immunotherapy AS on optimizing T cell receptors (TCRs) for subsequent implementation...
In a collaboration between researchers in Norway (Oslo University Hospital/University of Oslo and Nextera AS), USA (John Hopkins University) and Australia (Monash University), Nextera’s unique NextCore-Ab technology was employed to generate and characterize extremely sensitive TCR-Like antibodies towards gluten T cell epitopes. Their utility expand insight into celiac disease pathogenesis and opens the door for targeted therapeutic intervention
Oslo, Norway, 7. June, 2021 – Nextera AS, a drug and target discovery company built on a unique and novel phage display discovery platform, NextCore, announces the appointment of Dr. Bent Jakobsen to its Board of Directors.